Bialactis Biotech acquired by Biofabri

 

Biofabri announced today the purchase of 80% of Bialactis Biotech, a technological startup focused on the production and marketing of probiotics for human consumption, on Friday, 10 February. Previously owned by the two founding partners, they will retain 20% of the company.
Bialactis Biotech, located in Nigrán (in the region of Galicia, Spain), prepares and markets probiotics using bacteria generated by the human body to improve health and the immune system. The company is currently present with three types of products aimed at the pregnancy and lactation phase, for infants and adults, and performs nutritional, microbiological and immune analysis of maternal milk.
On 23 December, Biofabri acquired Probiserch, owned by Complutense University of Madrid. The company is involved in the identification and selection of bacterial strains for the manufacturing of probiotics.
With this new acquisition, the bio-pharmaceutical group including Biofabri and CZ Veterinaria, is reinforcing its commitment to a market niche –pharmaceutical-grade probiotics. This is the result of its expertise and technology for the industrial manufacturing of microorganisms.
The specific financial details of the acquisition were not revealed.
Biofabri, a bio-pharmaceutical company with a central focus on human healthcare, and its parent company, CZ Veterinaria, have formed a 100% Spanish bio-pharmaceutical group. CZV is a world leader in the production of microbacteria and is exclusively dedicated to the development and manufacturing of animal health vaccines and medications. The company manufactures proprietary products for distribution by third parties as well as a wide range of biologic and pharmacological products for multinational companies and governments across the world, and is present in over 65 countries.
Since 2008 Biofabri, S.A. has been researching, developing and manufacturing vaccines, medications and other products for human consumption. Some of Biofari’s most advanced projects include a tuberculosis vaccine, MTBVAC, currently in the clinical research phase.

Published in Spanish newspaper Faro de Vigo, 15 February 2017.